- Home
- NECB vs ZNTL Comparison
NECB vs ZNTL Comparison
Compare NECB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NECB | ZNTL |
|---|---|---|
| Founded | 1934 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.9M | 289.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NECB | ZNTL |
|---|---|---|
| Price | $25.66 | $3.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $30.00 | $6.60 |
| AVG Volume (30 Days) | 30.3K | ★ 777.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ 0.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | $34.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.27 | $1.13 |
| 52 Week High | $26.14 | $6.95 |
Technical Indicators
Market Signals| Indicator | NECB | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 46.32 |
| Support Level | $22.34 | $3.44 |
| Resistance Level | N/A | $4.38 |
| Average True Range (ATR) | 0.58 | 0.27 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 79.14 | 35.04 |
Price Performance
Historical ComparisonAbout NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States, including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.